Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC.MDGL · Entity 3441 | Director | June 16, 2022 | June 21, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
MADRIGAL PHARMACEUTICALS, INC.
Report date June 16, 2022 · Filed June 21, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $65.06 · Expires 2025-06-16 | Direct | 9,470 |
Reported balance
After 2022-06-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-06-16 · Grant · Acquired 9,470 · Balance 9,470 F1: The option vests as to 100% of underlying shares on the first anniversary of the grant date, provided that the Reporting Person continues to serve as a director of the Issuer until such anniversary date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests as to 100% of underlying shares on the first anniversary of the grant date, provided that the Reporting Person continues to serve as a director of the Issuer until such anniversary date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 16, 2022 Filed Jun 21, 2022 10:30 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | GrantStock Option (Right to Buy) · Derivative | 9,470 | $0.00 Strike: $65.06 | $0.00 |
DisclosureSEC source: 0000899243-22-023229 · doc4.xml · derivative · entry 1 Gollust Keith R · CIK 0001325712 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,470 Underlying: Common Stock · 9,470 shares Expires 2025-06-16 F1 · derivative.exercise_date: The option vests as to 100% of underlying shares on the first anniversary of the grant date, provided that the Reporting Person continues to serve as a director of the Issuer until such anniversary date. Read SEC document |
| June 17, 2021 Filed Jun 21, 2021 12:00 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | GrantStock Option (Right to Buy) · Derivative | 12,489 | $0.00 Strike: $105.08 | $0.00 |
DisclosureSEC source: 0000899243-21-024663 · doc4.xml · derivative · entry 1 Gollust Keith R · CIK 0001325712 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,489 Underlying: Common Stock · 12,489 shares Expires 2024-06-17 F1 · derivative.exercise_date: The option vests as to 100% of underlying shares on the first anniversary of the grant date, provided that the Reporting Person continues to serve as a director of the Issuer until such anniversary date. Read SEC document |
| June 17, 2020 Filed Jun 18, 2020 11:49 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | GrantStock Option (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $111.06 | $0.00 |
DisclosureSEC source: 0000899243-20-016990 · doc4.xml · derivative · entry 1 Gollust Keith R · CIK 0001325712 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2025-06-17 F1 · derivative.exercise_date: The option vests as to 100% of underlying shares on the first anniversary of the grant date, provided that the Reporting Person continues to serve as a director of the Issuer until such anniversary date. Read SEC document |
| June 27, 2019 Filed Jul 1, 2019 21:39 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $100.45 | $0.00 |
DisclosureSEC source: 0000899243-19-018644 · doc4.xml · derivative · entry 1 Gollust Keith R · CIK 0001325712 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2024-06-27 F1 · derivative.exercise_date: The option vests as to 100% of underlying shares on the first anniversary of the grant date, provided that the Reporting Person continues to serve as a director of the Issuer until such anniversary date. Read SEC document |
| June 19, 2018 Filed Jun 21, 2018 23:00 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $303.79 | $0.00 |
DisclosureSEC source: 0001179110-18-008926 · edgar.xml · derivative · entry 1 Gollust Keith R · CIK 0001325712 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2028-06-19 F1 · derivative.exercise_date: The option vests as to 100% of underlying shares on the first anniversary of the grant date, provided that the Reporting Person continues to serve as a director of the Issuer until such anniversary date. Read SEC document |
| June 29, 2017 Filed Jun 30, 2017 22:00 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $16.46 | $0.00 |
DisclosureSEC source: 0001179110-17-009844 · edgar.xml · derivative · entry 1 Gollust Keith R · CIK 0001325712 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2027-06-29 F1 · derivative.exercise_date: The option vests 100% on the first anniversary of the date of grant, provided that the Reporting Person continues to serve as a director of the Issuer until such anniversary date. Read SEC document |
| July 22, 2016 Filed Oct 24, 2016 23:11 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $12.01 | $0.00 |
DisclosureSEC source: 0001179110-16-030886 · edgar.xml · derivative · entry 1 Gollust Keith R · CIK 0001325712 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2026-07-22 F1 · derivative.exercise_date: Fifty percent (50%) of the option vests on July 22, 2017 and thereafter it vests at a rate of twelve and one-half percent (12.5%) per quarter for four (4) successive quarters. The filing is late due to an administrative oversight. Read SEC document |
| July 22, 2016 Filed Nov 4, 2016 21:16 UTC Amendment | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $9.45 | $0.00 |
DisclosureSEC source: 0001179110-16-031248 · edgar.xml · derivative · entry 1 Gollust Keith R · CIK 0001325712 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2026-07-22 F1 · derivative.exercise_price: This report amends the original report to reflect the correct exercise price of $9.45 per share. F2 · derivative.exercise_date: Fifty percent (50%) of the option vests on July 22, 2017 and thereafter it vests at a rate of twelve and one-half percent (12.5%) per quarter for four (4) successive quarters. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.